Elritercept (novel agent for myelofibrosis)
Current understanding
To be populated as evidence accumulates.
Evidence log
- June 12-15 — Advancing Frontiers in Myeloproliferative Neoplasms - EHA 2025 Congress Review: EHA 2025 congress review (review-level) highlights elritercept as a featured advance in myelofibrosis therapy, positioning it alongside pelabresib + ruxolitinib and CALR-directed immunotherapy in the current MF pipeline narrative. (novelty: 3)
- 2026-02-05 — A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis: Trial-early (Phase 1/2): Elritercept being evaluated as monotherapy and in combination with ruxolitinib in adults with myelofibrosis, with endpoints covering safety, tolerability, PK, anemia response, and MF signs/symptoms — first-in-class TGF-β superfamily ligand trap targeting the anemia axis in MF. (novelty: 4)
Open questions
Related
Contributing findings
Advancing Frontiers in Myeloproliferative Neoplasms - EHA 2025 Congress Review
June 12-15, 2025
novelty 3
per-area 4
introduces
New Drugs in Myelofibrosis: Incremental Progress in Symptom Management Without Disease Modification.
23-oct-2026
novelty 2
per-area 3
strengthens
Closing the disease modification gap: Emerging therapies in myelofibrosis beyond JAK inhibition.
30-jul-2026
novelty 2
per-area 2
mentions
A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis
05-feb-2026
novelty 4
per-area 5
introduces
EHA 2026 | Top abstracts in MPN
2026
novelty 2
per-area 2
mentions